1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors

Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
Product description

Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH) and for parathyroid hormone-related protein (PTHrP). FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), marketed since 2002 for the treatment of osteoporosis and related indications where an increase of bone mass is desirable. With 2012 sales of over US$ 1 bln and the forthcoming patent expiry, teriparatide is an attractive target for biosimilar developments as well as for next generation improved PTH receptor agonist products.

The present Competitive Intelligence report about PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors provides a competitor evaluation in the field of protein- and peptide-based agonists  of the parathyroid hormone (PTH) receptor for the treatment of osteoporosis as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors

Table of Contents

• 1st Generation PTH Receptor Agonists
• Teriparatide Biosimilars
• PTH-related Proteins/Peptides
• PTH Variants
• Nasal Drug Delivery Solutions for rhPTH Receptor Agonists
• Oral Drug Delivery Solutions for rhPTH Receptor Agonists
• Transdermal Drug Delivery Solutions for rhPTH Receptor Agonists
• Corporate PTH Receptor Agonist RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

  • $ 4550
  • Industry report
  • January 2017
  • by Hoovers Research

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present ...

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

  • $ 1500
  • Industry report
  • February 2017
  • by Kuick Research

“Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.